HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin

Abstract 

Recently two studies on the effect of addition of extended-release niacin to statin treatment on measures of carotid atherosclerosis were estimated in the ARBITER 6-HALTS study (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies) study and the Oxford Niacin Study were published. Adding niacin to statin treatment significantly diminished carotid atherosclerosis as measured by ultrasound carotid intima-media thickness or magnetic resonance imaging. An inhibitor of niacin induced flushing, laropiprant has been developed and demonstrated to considerably improve the tolerability of niacin therapy without impeding on its effect on lipoproteins. Still however clear evidence for the clinical benefit of long-term niacin treatment on cardiovascular morbidity and mortality is lacking. The development situation for ezetimibe is similar to that of niacin. Long-term interventional studies with hard endpoints of both therapies are ongoing. Also both drugs, when proven efficient and safe, are eagerly needed in the prevention of cardiovascular disease.

Keywords: Cardiovascular disease, Diabetes, Ezetimibe, Laropiprant, Niacin, Prevention

Abbreviations: CDP, Coronary Drug Project, IHDS, Ischaemic Heart Disease Study, HATS HDL, Atherosclerosis Treatment Study, n.r, not reported, QCA, Quantitative Coronary Angiography